RT Journal Article SR Electronic T1 Use of cell salvage and HBOC-201 in a pregnant Jehovah’s Witness with sickle beta+thalassaemia undergoing emergency caesarean section JF BMJ Case Reports JO BMJ Case Reports FD BMJ Publishing Group Ltd SP e251368 DO 10.1136/bcr-2022-251368 VO 15 IS 11 A1 Fortier, Julia A1 Pang, Shiyi A1 Schutte, Soleil A1 Zumberg, Marc Stuart A1 Rajasekhar, Anita YR 2022 UL http://casereports.bmj.com/content/15/11/e251368.abstract AB Patients with severe anaemia who refuse or cannot safely receive red cell transfusion present challenges during pregnancy, delivery and the postpartum period. Strategies including HBOC-201 (Hemopure) and intraoperative use of cell salvage have been used in non-pregnant patients to improve oxygen carrying capacity; however, these products pose unique risks in pregnant patients, those with sickle cell disease (SCD) and those undergoing caesarean section (C-section). We describe a case of a pregnant sickle beta+thalasasaemia patient who presented at 27 weeks gestation with pre-eclampsia and severe anaemia. As a Jehovah’s Witness, she declined allogenic blood transfusion. The patient successfully underwent emergent C-section with cell salvage and received HBOC-201 immediately after delivery, during the operative procedure. To our knowledge, this is the first published report documenting a Jehovah’s Witness patient with SCD who successfully received cell salvage and then HBOC-201 immediately postdelivery.